December 20, 2016

Novartis Pharma AG
CH-4002, Basel, Switzerland

Reference: EudraCT 2013-001643-30/ Novartis Protocol ID CLCZ696A2320

An 8-week randomized, double-blind, placebo-controlled factorial study to evaluate the efficacy and safety of LCZ696 alone and in combination with amlodipine in patients with essential hypertension

Trial CLCZ696A2320 was cancelled with no patient enrollment and as such, no results will be reported.